The implementation of spatial technologies advances disease research, but challenges must be overcome before spatial multi-omics becomes broadly accessible

The evolution of DNA sequencing – from Sanger to cutting-edge next generation approaches like Illumina, Nanopore and Single Molecule, Real-Time (PacBio) sequencing – has brought advances in speed, cost and accessibility. However, what challenges are faced in throughput scale-up, and what promise does automation hold for transforming genomics and personalised medicine?

While RNA molecules have demonstrated promising results as therapeutics for difficult-to-treat disease indications, their current limitations in terms of delivery mean their full potential is not being realised. How can this be overcome?

The pharma industry needs a way to ensure the right therapies are getting to the right patients, in a timely and cost-effective way. How are advances in researchers’ understanding of genomics aiding not only precision medicine for rare diseases, but also for common health conditions?

Cell line development is integral to research and biotherapeutic production, and so ensuring this process is as robust as possible through next-generation technology is in the industry’s best interests

How is current spatial biology being utilised in drug discovery and development for complex disease treatments, and how can it be improved?

Considering the importance and cost associated with oligonucleotide-based therapeutics, how can innovative computing imaging techniques be used to aid in the process, while also creating an audit trail and increasing the data derived from these experiments?

Since the completion of the human genome project in 2003, there has been huge growth in the utilisation of genomics, but how can partnerships in this area be used to improve patient experience

Synthetic biology has been a cornerstone in recent health advancements, including drug discovery, development and manufacturing, however there are challenges facing this market

The development and use of novel gene therapy approaches is increasing. With the advent of innovative technologies using improved tropism and safer viral-based systems, and nanotechnology advancing non-viral delivery of nucleic acid vectors, there will be more gene-based products entering the market in near future

IPT talks with Jacob Tesdorpf at Revvity about the recent developments in preclinical imaging, from AI-enchanced analysis to refined disease models

The World Health Organization (WHO) has recognised the scarcity of new antimicrobial agents in the clinical pipeline. The prevailing approach to combatting antimicrobial resistance cannot solely rely on developing new drugs. Instead, we must seek ways to better understand and more efficiently use the drugs already at our disposal.